Objective: Determine subject satisfaction with onabotulinumtoxinA treatment of glabellar lines (GL) and lateral canthal lines (LCL) using the Facial Line Satisfaction Questionnaire (FLSQ ® ), a recently developed and validated patient-reported outcome measure.
Results:
Of 125 subjects enrolled in the study, 117 (mean age, 46.5 years; females, 83.8%) met the criteria for the per-protocol analysis. Most subjects (81.7.0%) receiving onabotulinumtoxinA were "satisfied"/"very satisfied" with treatment effect on GL and LCL at the primary time point of day 60 versus placebo (0%; P<.001). Similar results were seen at all time points. Treatment exceeded or met expectations in at least 86% of subjects at all time points (Figure 1 ). On the FWS, 83.3% and 86.7% of subjects achieved none or mild for GL and at least a 1-grade improvement for LCL at day 30 versus placebo (1.8% and 8.8%, respectively; Figure 2 ). Most subjects were "improved"/"much improved" on the GAIS at day 60 as assessed by the investigator and subject (86.7% and 83.3%, respectively). Adverse events were infrequent and typical of those seen in similar clinical trials, with 6 subjects experiencing 7 onabotulinumtoxinArelated adverse events (one moderate [headache], the rest mild in severity). No subjects experienced ptosis. 
